Israel's Medison sets up JV with AltaRex

11 July 2000

Israeli biotechnology company Medison Pharma has signed an agreementwith AltaRex Corp to establish a 50:50 joint venture to commercialize OvaRex MAb for the treatment of ovarian cancer and other oncology products in Israel and the Middle East.

AltaRex estimates that in the region covered by the JV, OvaRex alone represents potential sales of some $5 million annually. Medison currently markets products in the region for firms such as Biogen, Sangstat, Beaufour Ipsen, Nycomed Amersham and Antigenics.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight